Speaker 1: Bloomberg Audio Studios, podcasts, radio news.
Speaker 2: The Stock Movers Report, your roundup of companies making moves
Speaker 2: in the stock market, harnessing the power of Bloomberg data.
Speaker 3: Now, let's look at some of the stocks on the
Speaker 3: move today here in Europe. I'm Caroline Hepget and I'm
Speaker 3: joined by Blueberg reporter Cloim mala Cloy. Good morning. So
Speaker 3: it's been cult outside, but it might just be the
Speaker 3: right time for ice cream still. Maybe is it Unilever's
Speaker 3: Magnum deal.
Speaker 1: Yeah, absolutely so.
Speaker 4: Magnum ice Cream Company has started trading today in London,
Speaker 4: Amsterdam and a little bit later in New York. So
Speaker 4: the spin off of the ice cream unit for the
Speaker 4: Unilever is now completed. It happened a month later than
Speaker 4: originally planned because it was pushed back because of the
Speaker 4: US government has shut down.
Speaker 1: So now the focus is really going to be.
Speaker 4: On Unilever's prospects as a standalone company, and given how
Speaker 4: shares fell today for unile but perhaps the investor enthusiasm
Speaker 4: isn't really there at the moment. And then for Magnum itself,
Speaker 4: for this new company, they are also challenges of course
Speaker 4: as well, So there's obviously a growing number of really
Speaker 4: health conscious consumers, maybe people that don't necessarily want to
Speaker 4: have ice cream. There's obviously, of course weight loss drugs
Speaker 4: which limit appetite. And then it's also quite a capital
Speaker 4: intensive business. So this is a part of Unilever that
Speaker 4: was dealing with quite high production costs, quite high storage costs,
Speaker 4: and that really weighed on margins. That's part of the
Speaker 4: reason why there was a push to demerge that company.
Speaker 1: But now perhaps Magnum can refocus.
Speaker 4: The management team is quite well regarded by analysts, and
Speaker 4: analysts are saying that the company can now really reinvest
Speaker 4: in growth and really refocus after it really was all
Speaker 4: about returns and cash under Unilever.
Speaker 1: So we'll see how that goes.
Speaker 4: But yeah, it's an interesting time of year to be
Speaker 4: to be listing an ice cream business. Yeah.
Speaker 1: Absolutely.
Speaker 3: Apparently in the UK, in the factory they make about
Speaker 3: six hundred million ice creams a year, the vast majority
Speaker 3: for people here in the UK. So yes, we're still
Speaker 3: eating the odd Madner, I would argue.
Speaker 1: I am, and I am right.
Speaker 3: Secondly, Skins Care in the Spotlight with Galderma, I read
Speaker 3: that this morning. I can't say I know that name.
Speaker 3: What's the story there?
Speaker 4: So Loreal has double this steak in Galderma this morning.
Speaker 4: So gal Demo is a company that is in skincareess
Speaker 4: but is known primarily for making injectibles so botox, fillers,
Speaker 4: et cetera. But then just in the kind of wider
Speaker 4: dermatology space. So now the steak from Loreal is now
Speaker 4: twenty percent, So that is doubled from the ten percent
Speaker 4: that Loreal took last year. So it's really reinforcing that
Speaker 4: investment in dermatology and trying to gain maybe a stronger
Speaker 4: foothold as well in that injectibles market. And Liz have
Speaker 4: said that the investment makes a lot of strategic sense.
Speaker 4: You've got one company that has got their leadership in dermatology,
Speaker 4: and then the other kind of brings that expertise as
Speaker 4: a leading beauty company. Of course, Loreal being such a
Speaker 4: big name, Galdamahs were up on the back of that,
Speaker 4: but Lories are actually down, so it might be because
Speaker 4: of Laura has been making so many deals recently. I
Speaker 4: recently bought a South Korean brand called dr G. It
Speaker 4: took a majority stake in a UK skincare brand called Medicaid,
Speaker 4: so perhaps one too many deal for investors at this morning,
Speaker 4: but for Galdermo was definitely seen as a positive.
Speaker 3: Interesting, Maybe is it me or do I relate?
Speaker 1: Is it may just be me?
Speaker 3: Kate Winslet was talking about injectables and beauty just over
Speaker 3: the weekend.
Speaker 1: I got picked up very widely. I saw did you
Speaker 1: see that?
Speaker 3: Yeah, obviously very beautiful actress saying you know, we should
Speaker 3: have the natural look was which I thought was interesting. Now,
Speaker 3: in terms of Monte Pasci, Monte Tepasci reaffirming confidence in
Speaker 3: its CEO. What about this bank?
Speaker 4: Yeah, so it reaffirmed that their confidence kind of reaffirmed
Speaker 4: its support for the CEO's currently caught in a probe
Speaker 4: into a takeover of Medio Banker. So Luis gilovaglio Is,
Speaker 4: who's the CEO, is currently being investigated by prosecutors for
Speaker 4: allegedly coordinating this Medio Banker acquisition with two big investors.
Speaker 4: So that probe has really weighed on the shares, but
Speaker 4: there seems to be maybe some relief from Montepesci. The
Speaker 4: market regulator in Italy has ruled out the existence of
Speaker 4: an undisclosed investor pact that involves PASKI and some of
Speaker 4: its shareholders in that bid for Medio Banker, So that
Speaker 4: development and then also the bank reaffirming that support and
Speaker 4: that confidence in the CEO has been supporting that share
Speaker 4: price today. So quite a good day for Pesci after
Speaker 4: a lot of weakness over the last couple of weeks.
Speaker 2: The Stock Movers Report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com and on Applecarplay. And Andrew writ Auto
Speaker 2: with the Bloomberg Business app.
Speaker 3: Mm hmm